GlaxoSmithKline To Cut Hundreds Of U.S. Jobs Before Year’s End

0
GlaxoSmithKline To Cut Hundreds Of U.S. Jobs Before Year’s End
By Ian Wilson (Flickr) [<a href="http://creativecommons.org/licenses/by/2.0">CC BY 2.0</a> or <a href="http://creativecommons.org/licenses/by/2.0">CC BY 2.0</a>], <a href="https://commons.wikimedia.org/wiki/File%3AGlaxoSmithKline_building%2C_London%2C_30_July_2007.jpg">via Wikimedia Commons</a>

With the announced cuts coming before the end of the year, “hundreds” are set to have a less than Merry Christmas.

It’s likely that the employees affected have been told or will be shortly, but so far details are not forthcoming. Dierdre Connelly, who heads North American operations, has stated that the drug-maker is looking to cut costs by $1.6 billion over the next three years with the bulk of this cutting to be reflected in its 2016 balance sheet. The company first announced this cost cutting in October of this year.

Odey Special Situations Fund took on several new positions in March

Crispin OdeyOdey Asset Management's Special Situations Fund was down 3.2% in March, compared to its benchmark, the MSCI World USD Index, which was up 3.3%. Through the end of March, the fund is up 8.7%, beating the benchmark's return of 4.9%. Q1 2021 hedge fund letters, conferences and more Odey's Special Situations Fund deploys arbitrage and Read More


GlaxoSmithKline’s employees to begin to hear details today

A spokesperson for the company recently told the Wall Street Journal that the cost cutting “is to improve performance by taking unnecessary complexity out of our operations and establish a smaller, more focused, organization, operating at lower costs that support our future portfolio. Each business unit is currently deciding how to respond to this challenge.” When asked for further details, she declined stating, “When we do have proposals, we will first share those with our employees.”

The cuts are not a terrific surprise given the company’s third quarter sales results which fell 11% in GlaxoSmithKline plc (ADR) (NYSE:GSK) (LON:GSK)’s biggest market (The U.S.). The drop was primarily due to poor sales of its best-selling product Advair.

Reorganization of GlaxoSmithKline’s R&D facilities

Of the 99,000 employees that GlaxoSmithKline plc (ADR) (NYSE:GSK) (LON:GSK) has working for it worldwide, 17,000 of them are based in the United States and its believed that the bulk of the cuts will occur at the company’s North Carolina R&D site as the company looks to streamline its research and development given “market changes, evolving customer needs and the overall U.S. business environment.” GSX , in a letter of intent, spoke of its desire to shift around 450 of its R&D staff in Research Triangle Park, near Durham, N.C. to Parexel International and create a dedicated GSK business unit within PAREXEL. That shift will “provide a variety of clinical development services and be largely based in the RTP area,” according to a release from GSK.

In addition to R&D restructuring and reorganization, sales and marketing employees are also on the chopping block though to a considerably lesser extent.

GlaxoSmithKline plc (ADR) (NYSE:GSK) (LON:GSK) will pare its Research Triangle Park R&D team and consolidate its R&D around its sites in the Philadelphia region and at Stevenage, U.K. It’s believed that some North Carolina workers will be offered a chance to relocated to one of these sites.

Previous article China’s Fosun To Outbid Italy’s Andrea Bonomi For Club Med
Next article What will the end of cheap Chinese labour mean for Canadians?
While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. <i>To contact Brendan or give him an exclusive, please contact him at [email protected]</i>

No posts to display